glaucoma

Sustained-release topical rings promising for glaucomaA single bimatoprost topical ring has been shown to be effective and safe for lowering IOP over six months, according to results from a phase II study.
NASEM declares eye health a public health imperativeIn order to avoid a public health crisis and keep up with increasing vision loss among the aging baby-boomer generation, correctable vision impairments must be eliminated by 2030, according to a report issued by the National Academies of Sciences, Engineering, and Medicine (NASEM).
Charting new directions in glaucoma treatmentBen Gaddie, OD, FAAO, Optometry Times Editorial Advisory Board member, noted several specific areas that were advancing to give ODs better data and better control over patient health outcomes, including: • Corneal mechanics • 24-hour IOP monitoring • New glaucoma drugs and drug delivery systems • Advancements in OCT imaging
ECPs don’t treat glaucoma aggressively enoughGlaucoma isn’t being treated aggressively enough, and eyecare practitioners are being too cautious when it comes to treating and diagnosing the disease—often at the patient’s expense.
Exploring SLT efficacy for prior incisional glaucoma surgerySelective laser trabeculoplasty is a reasonable treatment option to reduce IOP in glaucoma patients who have had previous glaucoma surgery.
Tablet-based tests putting detection of glaucoma at handAn iPad-based quick contrast sensitivity test had similar sensitivity and specificity to frequency-doubling technology.
Continuous IOP monitoring: Tools for addressing an unmet need
Continuous IOP monitoring: Tools for addressing an unmet needDevices for continuous IOP monitoring will address the need to better understand IOP levels and patterns in patients with glaucoma.
New technology predicts conversion to POAGClinicians can predict which patients with ocular hypertension are most likely to develop primary open-angle glaucoma (POAG) using short-wave automated perimetry, scanning laser polimetry, and confocal laser ophthalmoscopy, as well as the patient’s age, researchers said.
Microstent approval makes big news in glaucoma world
Microstent approval makes big news in glaucoma worldClinicians will soon have another treatment option for their patients with non-severe primary open-angle glaucoma (POAG). A micro invasive glaucoma surgical (MIGS) device (CyPass Micro-Stent, Alcon) has been approved by the FDA for use in patients with mild-moderate PAOG in conjunction with cataract surgery.
ABiC targets all sites of outflow resistanceAb-interno canaloplasty (ABiC) is a minimally invasive glaucoma surgery that accesses, catheterizes, and viscodilates all sites controlling aqueous outflow. When performed alone for uncontrolled glaucoma or with cataract surgery, it can result in reduced IOP and daily medication at follow-up through 12 months.